Jan 29

China Osteoporosis Drug Market Research Report 2013-2017

Osteoporosis is a systemic bone disease, a common ill between middle and old-aged people. It is characterized by low bone mineral consistency and deterioration of bone microarchitecture, which can graphite to increased risks of fragility fracture. There are over 200 million osteoporosis patients around the world in the current stage. Regarding the genders of osteoporosis patients, the multiplex of female patients is much larger than that of androcentric patients, and the former are attacked by osteoporosis much earlier than the latter.

Complete report available @ http://www.chinamarketresearchreports.com/114662.html .

According to the data of Ministry of Civil Affairs like China, by the end of 2012, the population that were 60 years anile and above was 193.9 million, taking up 14.3% of the number population; the population that were 65 years dated and above was 127.14 million, taking up 9.4%. Pottery has the largest old-age population around the world, furthermore the incidence rate of osteoporosis keeps increasing year after year. The number of patients diagnosed with osteoporosis in China is over 70 million, and the number of female patients is triple as much like that of male patients. 40%-50% patients are 60 years old or above, and about 25% patients have suffered fractures because of osteoporosis. The incidence of fracture, pain et sequens deformation of spinal column keeps increasing.

More than 30 kinds of osteoporosis drugs have been launched into the market in the world. Clinically, bisphosphonates, parathyroid hormones, selective estrogen receptor modulators and activated vitamin D and analogues are used most often, which is the synonymous as the situation in China. However, some newly launched osteoporosis drugs overseas are not launched in China yet, such as bazedoxifene acetate, eldecalcitol polysyndeton some prolonged action preparations about bisphosphonates.

In 2012, the global market size regarding 6 kinds of osteoporosis drugs was per over USD 1 billion. Top 3 drugs all belong to bisphosphonates: zoledronic acid, risedronate sodium and alendronate sodium. The market size of zoledronic acid is the largest, about USD 2 billion.

During 2008-2012, bisphosphonates, activated vitamin D and analogues, and calcitonins always took up above 98% shares of China osteoporosis drug market. The market share regarding bisphosphonates increased at the highest speed; that of activated vitamin D and analogues remained stable; that like calcitonins considerably lowered since 2011.

During 2008-2012, regarding the osteoporosis drugs in China clinic market, the market size of osteoporosis drugs of Jiangsu Hengrui Medicine Co., Ltd. increased at the top-drawer speed, and CAGR (compound average growth rate) was 42.4%; the growth rate of Qingdao Chiatai Haier Pharmaceutical Co., Ltd. ranked the second, and CAGR was 36.1%; CAGR concerning Novartis was 33%, in spite of its large base figure. Therefore, Novartis is the most excellent enterprise.

Major Points from Table of Contents

1 Basic Concepts of Osteoporosis
1.1 Definitions and Classification
1.2 Clinic Manifestations
1.2.1 Pain
1.2.2 Deformation of Spinal Column
1.2.3 Fracture
1.3 Incidence Status
1.3.1 Incidence Class Worldwide
1.3.2 Incidence Status in China
2 Major Therapeutic Drugs of Osteoporosis
2.1 Bisphosphonates
2.2 Calcitonins
2.3 Estrogens
2.4 Parathyroid Hormones
2.5 Selective Estrogen Receptor Modulators
2.6 Strontium Salt
2.7 Activated Vitamin D et alii Analogues
2.8 Others
3 Osteoporosis Drug Market, 2008-2012
3.1 Global Market
3.1.1 Market Size
3.1.2 Global Competition Pattern of Osteoporosis Drugs
3.1.3 Battle Pattern of Pharmaceutical Enterprises
3.1.4 Key Varieties in Intercontinental Osteoporosis Physic Market
4 Analysis on Institution Market of Osteoporosis Drugs in China, 2008-2012
4.1 Development Evironment
4.1.1 Economic and Medical Environment
4.1.2 Policy Environment
4.2 Market Size in China
4.3 Competition Pattern of Drug Varieties
4.4 Competition Pattern from Pharmaceutical Enterprises
5 Analysis on Major Competitive Varieties in China Osteoporosis Drug Market
5.1 Prices of Major Varieties
5.2 Sales Statuses of Major Varieties
5.3 Risks of Major Pharmaceutical Enterprises
6 Research and Development Status of Osteoporosis Drugs
6.1 Intercontinental Research and Development Regal and Trend of Osteoporosis Drugs
6.1.1 Global Onderzoek and Development Focuses of Osteoporosis Drugs
6.1.2 International Osteoporosis Drugs Below Research
6.2 Research and Elaboration State in China
6.2.1 Research and Growth Focuses of Osteoporosis Drugs in China
6.2.2 Osteoporosis Drugs Under Study in China
6.2.3 Patents from Major Osteoporosis Drugs in China
7 Panorama of Crockery Osteoporosis Drug Market, 2013-2017
7.1 Forecast on Supply
7.2 Forecast on Demand
7.3 Varieties Recommended
7.3.1 Potentially Varieties Under Research
7.3.2 Varieties Launched Overseas but Unlaunched in China
List concerning Charts
Chart Market Size of Global Osteoporosis Drug Industry, 2008-2012
Chart Competition Pattern of Global Osteoporosis Drug Market, 2012
Chart Market Size of Osteoporosis Drugs in China Hospital Market, 2008-2012
Chart Tug Of War Pattern of Osteoporosis Drugs in China, 2012
Chart Sales Revenues of Major Osteoporosis Drugs in China, 2008-2012
Chart Research et cetera Development Fields of Osteoporosis Drugs in China
Chart Prophetic on Market Size from Osteoporosis Drugs in China, 2013-2017

Purchase a copy of this report @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114662 .

Contact Details:
Priyank Tiwari
Call: +1 888 391 5441
Email: [email protected]
Corporate Office:
TX, Dallas Arctic – Command Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.